Hepatitis Monthly

Published by: Kowsar

The Therapeutic Use of Analgesics in Patients With Liver Cirrhosis: A Literature Review and Evidence-Based Recommendations

Farnad Imani 1 , Mahsa Motavaf 2 , 3 , Saeid Safari 1 and Seyed Moayed Alavian 3 , 4 , *
Authors Information
1 Department of Anesthesiology and Pain Medicine, Iran University of Medical Sciences, Tehran, IR Iran
2 Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, IR Iran
3 Department of Molecular Hepatology, Middle East Liver Disease Center, Tehran, IR Iran
4 Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
Article information
  • Hepatitis Monthly: October 01, 2014, 14 (10); e23539
  • Published Online: October 11, 2014
  • Article Type: Review Article
  • Received: September 11, 2014
  • Revised: September 30, 2014
  • Accepted: October 4, 2014
  • DOI: 10.5812/hepatmon.23539

To Cite: Imani F, Motavaf M, Safari S, Alavian S M. The Therapeutic Use of Analgesics in Patients With Liver Cirrhosis: A Literature Review and Evidence-Based Recommendations, Hepat Mon. 2014 ; 14(10):e23539. doi: 10.5812/hepatmon.23539.

Abstract
Copyright © 2014, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
Footnote
References
  • 1. Lim YS, Kim WR. The global impact of hepatic fibrosis and end-stage liver disease. Clin Liver Dis. 2008; 12(4): 733-46[DOI][PubMed]
  • 2. Graudal N, Leth P, Marbjerg L, Galloe AM. Characteristics of cirrhosis undiagnosed during life: a comparative analysis of 73 undiagnosed cases and 149 diagnosed cases of cirrhosis, detected in 4929 consecutive autopsies. J Intern Med. 1991; 230(2): 165-71[PubMed]
  • 3. Alavian SM, Fallahian F, Lankarani KB. The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis. 2007; 16(4): 403-6[PubMed]
  • 4. Keyvani H, Bokharaei-Salim F, Monavari SH, Esghaei M, Nassiri Toosi M, Fakhim S, et al. Occult hepatitis C virus infection in candidates for liver transplant with cryptogenic cirrhosis. Hepat Mon. 2013; 13(8)[DOI][PubMed]
  • 5. Rossi S, Assis DN, Awsare M, Brunner M, Skole K, Rai J, et al. Use of over-the-counter analgesics in patients with chronic liver disease: physicians' recommendations. Drug Saf. 2008; 31(3): 261-70[PubMed]
  • 6. Imani F, Safari S. “Pain Relief is an Essential Human Right”, We Should be Concerned about It. Anesth Pain Med. 2011; 1(2): 55-7
  • 7. Elbekai RH, Korashy HM, El-Kadi AO. The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes. Curr Drug Metab. 2004; 5(2): 157-67[PubMed]
  • 8. Bohan A, Boyer JL. Mechanisms of hepatic transport of drugs: implications for cholestatic drug reactions. Semin Liver Dis. 2002; 22(2): 123-36[DOI][PubMed]
  • 9. Rahimzadeh P, Safari S, Faiz SH, Alavian SM. Anesthesia for patients with liver disease. Hepat Mon. 2014; 14(7)[DOI][PubMed]
  • 10. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008; 64(12): 1147-61[DOI][PubMed]
  • 11. Safari S, Motavaf M, Seyed Siamdoust SA, Alavian SM. Hepatotoxicity of Halogenated Inhalational Anesthetics. Iran Red Crescent Med J. 2014; 16(9)[DOI]
  • 12. Mohseni M, Safari S, Alavian SM. Volatile anesthetics in ischemic liver injury: enemy or friend? Hepat Mon. 2014; 14(6)[DOI][PubMed]
  • 13. Blaschke TF, Rubin PC. Hepatic first-pass metabolism in liver disease. Clin Pharmacokinet. 1979; 4(6): 423-32[PubMed]
  • 14. Delco F, Tchambaz L, Schlienger R, Drewe J, Krahenbuhl S. Dose adjustment in patients with liver disease. Drug Saf. 2005; 28(6): 529-45[PubMed]
  • 15. Hoyumpa AM, Schenker S. Is glucuronidation truly preserved in patients with liver disease? Hepatology. 1991; 13(4): 786-95[PubMed]
  • 16. Debinski HS, Lee CS, Danks JA, Mackenzie PI, Desmond PV. Localization of uridine 5'-diphosphate-glucuronosyltransferase in human liver injury. Gastroenterology. 1995; 108(5): 1464-9[PubMed]
  • 17. Graham GG, Scott KF, Day RO. Tolerability of paracetamol. Drug Saf. 2005; 28(3): 227-40[PubMed]
  • 18. Arnman R, Olsson R. Elimination of paracetamol in chronic liver disease. Acta Hepatogastroenterol (Stuttg). 1978; 25(4): 283-6[PubMed]
  • 19. Andreasen PB, Hutters L. Paracetamol (acetaminophen) clearance in patients with cirrhosis of the liver. Acta Med Scand Suppl. 1979; 624: 99-105[PubMed]
  • 20. Alimian M, Pournajafian A, Kholdebarin A, Ghodraty M, Rokhtabnak F, Yazdkhasti P. Analgesic effects of paracetamol and morphine after elective laparotomy surgeries. Anesth Pain Med. 2014; 4(2)[DOI][PubMed]
  • 21. Benson GD, Koff RS, Tolman KG. The therapeutic use of acetaminophen in patients with liver disease. Am J Ther. 2005; 12(2): 133-41[PubMed]
  • 22. Kuffner EK, Green JL, Bogdan GM, Knox PC, Palmer RB, Heard K, et al. The effect of acetaminophen (four grams a day for three consecutive days) on hepatic tests in alcoholic patients--a multicenter randomized study. BMC Med. 2007; 5: 13[DOI][PubMed]
  • 23. Heard K, Green JL, Bailey JE, Bogdan GM, Dart RC. A randomized trial to determine the change in alanine aminotransferase during 10 days of paracetamol (acetaminophen) administration in subjects who consume moderate amounts of alcohol. Aliment Pharmacol Ther. 2007; 26(2): 283-90[DOI][PubMed]
  • 24. Lucena MI, Andrade RJ, Tognoni G, Hidalgo R, Sanchez de la Cuesta F, Spanish Collaborative Study Group on Therapeutic Management of Liver D. Drug use for non-hepatic associated conditions in patients with liver cirrhosis. Eur J Clin Pharmacol. 2003; 59(1): 71-6[DOI][PubMed]
  • 25. Khalid SK, Lane J, Navarro V, Garcia-Tsao G. Use of over-the-counter analgesics is not associated with acute decompensation in patients with cirrhosis. Clin Gastroenterol Hepatol. 2009; 7(9): 994-9[DOI][PubMed]
  • 26. Watkins PB, Kaplowitz N, Slattery JT, Colonese CR, Colucci SV, Stewart PW, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA. 2006; 296(1): 87-93[DOI][PubMed]
  • 27. American Liver Foundation . The American Liver Foundation Issues Warning on Dangers of Excess Acetaminophen. American Liver Foundation. 2006;
  • 28. Chandok N, Watt KD. Pain management in the cirrhotic patient: the clinical challenge. Mayo Clin Proc. 2010; 85(5): 451-8[DOI][PubMed]
  • 29. Schoene B, Fleischmann RA, Remmer H, von Oldershausen HF. Determination of drug metabolizing enzymes in needle biopsies of human liver. Eur J Clin Pharmacol. 1972; 4(2): 65-73[PubMed]
  • 30. Williams RL, Upton RA, Cello JP, Jones RM, Blitstein M, Kelly J, et al. Naproxen disposition in patients with alcoholic cirrhosis. Eur J Clin Pharmacol. 1984; 27(3): 291-6[PubMed]
  • 31. Hartleb M, Gutkowski K. Kidneys in chronic liver diseases. World J Gastroenterol. 2012; 18(24): 3035-49[DOI][PubMed]
  • 32. Wong F, Massie D, Hsu P, Dudley F. Indomethacin-induced renal dysfunction in patients with well-compensated cirrhosis. Gastroenterology. 1993; 104(3): 869-76[PubMed]
  • 33. Laffi G, La Villa G, Pinzani M, Marra F, Gentilini P. Arachidonic acid derivatives and renal function in liver cirrhosis. Semin Nephrol. 1997; 17(6): 530-48[PubMed]
  • 34. Arroyo V, Gines P, Rimola A, Gaya J. Renal function abnormalities, prostaglandins, and effects of nonsteroidal anti-inflammatory drugs in cirrhosis with ascites. An overview with emphasis on pathogenesis. Am J Med. 1986; 81(2B): 104-22[PubMed]
  • 35. O'Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett. 1993; 330(2): 156-60[PubMed]
  • 36. Morita I. Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat. 2002; 68-69: 165-75[PubMed]
  • 37. Perez-Ayuso RM, Arroyo V, Camps J, Rimola A, Gaya J, Costa J, et al. Evidence that renal prostaglandins are involved in renal water metabolism in cirrhosis. Kidney Int. 1984; 26(1): 72-80[PubMed]
  • 38. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A. 1999; 96(13): 7563-8[PubMed]
  • 39. Peck-Radosavljevic M. Review article: coagulation disorders in chronic liver disease. Aliment Pharmacol Ther. 2007; 26 Suppl 1: 21-8[DOI][PubMed]
  • 40. De Ledinghen V, Heresbach D, Fourdan O, Bernard P, Liebaert-Bories MP, Nousbaum JB, et al. Anti-inflammatory drugs and variceal bleeding: a case-control study. Gut. 1999; 44(2): 270-3[PubMed]
  • 41. Ackerman Z, Cominelli F, Reynolds TB. Effect of misoprostol on ibuprofen-induced renal dysfunction in patients with decompensated cirrhosis: results of a double-blind placebo-controlled parallel group study. Am J Gastroenterol. 2002; 97(8): 2033-9[DOI][PubMed]
  • 42. Laffi G, Daskalopoulos G, Kronborg I, Hsueh W, Gentilini P, Zipser RD. Effects of sulindac and ibuprofen in patients with cirrhosis and ascites. An explanation for the renal-sparing effect of sulindac. Gastroenterology. 1986; 90(1): 182-7[PubMed]
  • 43. Zipser RD, Hoefs JC, Speckart PF, Zia PK, Horton R. Prostaglandins: modulators of renal function and pressor resistance in chronic liver disease. J Clin Endocrinol Metab. 1979; 48(6): 895-900[DOI][PubMed]
  • 44. Arroyo V, Planas R, Gaya J, Deulofeu R, Rimola A, Perez-Ayuso RM, et al. Sympathetic nervous activity, renin-angiotensin system and renal excretion of prostaglandin E2 in cirrhosis. Relationship to functional renal failure and sodium and water excretion. Eur J Clin Invest. 1983; 13(3): 271-8[PubMed]
  • 45. Claria J, Kent JD, Lopez-Parra M, Escolar G, Ruiz-Del-Arbol L, Gines P, et al. Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. Hepatology. 2005; 41(3): 579-87[DOI][PubMed]
  • 46. Brater DC, Anderson SA, Brown-Cartwright D. Reversible acute decrease in renal function by NSAIDs in cirrhosis. Am J Med Sci. 1987; 294(3): 168-74[PubMed]
  • 47. Bosch-Marce M, Claria J, Titos E, Masferrer JL, Altuna R, Poo JL, et al. Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites. Gastroenterology. 1999; 116(5): 1167-75[PubMed]
  • 48. Lopez-Parra M, Claria J, Planaguma A, Titos E, Masferrer JL, Woerner BM, et al. Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites. Br J Pharmacol. 2002; 135(4): 891-900[DOI][PubMed]
  • 49. Harris RC. COX-2 and the kidney. J Cardiovasc Pharmacol. 2006; 47 Suppl 1-42[PubMed]
  • 50. Hasselstrom J, Eriksson S, Persson A, Rane A, Svensson JO, Sawe J. The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. Br J Clin Pharmacol. 1990; 29(3): 289-97[PubMed]
  • 51. Hajiesmaeili MR, Safari S. Pain management in the intensive care unit: do we need special protocols? Anesth Pain Med. 2012; 1(4): 237-8[DOI][PubMed]
  • 52. Eydi M, Golzari SE, Aghamohammadi D, Kolahdouzan K, Safari S, Ostadi Z. Postoperative Management of Shivering: A Comparison of Pethidine vs. Ketamine. Anesth Pain Med. 2014; 4(2)[DOI][PubMed]
  • 53. Imani F, Faiz HR, Sedaghat M, Hajiashrafi M. Effects of adding ketamine to fentanyl plus acetaminophen on postoperative pain by patient controlled analgesia in abdominal surgery. Anesth Pain Med. 2014; 4(1)[DOI][PubMed]
  • 54. Durnin C, Hind ID, Ghani SP, Yates DB, Molz KH. Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in subjects with moderate hepatic impairment. Proc West Pharmacol Soc. 2001; 44: 83-4[PubMed]
  • 55. Tallgren M, Olkkola KT, Seppala T, Hockerstedt K, Lindgren L. Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation. Clin Pharmacol Ther. 1997; 61(6): 655-61[DOI][PubMed]
  • 56. Moradi M, Esmaeili S, Shoar S, Safari S. Use of oxycodone in pain management. Anesth Pain Med. 2012; 1(4): 262-4[DOI][PubMed]
  • 57. Smith HS. Opioid metabolism. Mayo Clin Proc. 2009; 84(7): 613-24[DOI][PubMed]
  • 58. Iribarne C, Picart D, Dreano Y, Bail JP, Berthou F. Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sci. 1997; 60(22): 1953-64[PubMed]
  • 59. Franz CC, Egger S, Born C, Ratz Bravo AE, Krahenbuhl S. Potential drug-drug interactions and adverse drug reactions in patients with liver cirrhosis. Eur J Clin Pharmacol. 2012; 68(2): 179-88[DOI][PubMed]
  • 60. Lee YC, Chang CH, Lin JW, Chen HC, Lin MS, Lai MS. Non-steroidal anti-inflammatory drugs use and risk of upper gastrointestinal adverse events in cirrhotic patients. Liver Int. 2012; 32(5): 859-66[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments